Insulin Lispro
C257H383N65O77S6
5807.57
Insulin (human), 28B-l-lysine-29B-l-proline-;
28B-l-Lysine-29B-l-prolineinsulin (human) [133107-64-9]
Insulin (human), 28B-l-lysine-29B-l-proline-;
28B-l-Lysine-29B-l-prolineinsulin (human) [133107-64-9]
DEFINITION
Insulin Lispro is identical in structure to Insulin Human, except that it has lysine and proline at positions 28 and 29, respectively, of the B-chain, whereas this sequence is reversed in Insulin Human. Insulin Lispro is produced by methods based on recombinant DNA technology. The presence of host cell DNA in Insulin Lispro is process-specific. The capability of the process to clear host-derived DNA requires validation and is determined by validated methods. Its potency is NLT 27.0 USP Insulin Lispro Units/mg, calculated on the dried basis.